| 基因名 | 疾病 | 靶向药 | 化疗药 | 基因突变 | 临床解释 |
|---|---|---|---|---|---|
| FZR1 | 0 | 0 | |||
| FZD10 | 0 | 0 | |||
| FZD1 | 0 | 0 | |||
| FYN | 0 | 0 | |||
| FXR1 | 0 | 0 | |||
| FUS | 0 | 0 | |||
| FUBP1 | 0 | 0 | |||
| FSCB | 0 | 0 | |||
| FRYL | 0 | 0 | |||
| FRS2 | 0 | 0 | |||
| FRMPD4 | 0 | 0 | |||
| FRK | 0 | 0 | |||
| FRG1 | 0 | 0 | |||
| FRAS1 | 0 | 0 | |||
| FPGS | 0 | 0 | |||
| FOXQ1 | 0 | 0 | |||
| FOXP3 | 乳腺癌 | 表柔比星, | 1 | 1 | |
| FOXP1 | 弥漫性大B细胞淋巴瘤 | 1 | 1 | ||
| FOXO4 | 0 | 0 | |||
| FOXO3 | 脉络丛癌 | 1 | 2 | ||
| FOXO1 | 肺泡横纹肌肉瘤 | Bromodomain Inhibitor, | 2 | 3 | |
| FOXL2 | 卵巢颗粒细胞瘤 | 1 | 2 | ||
| FOXA2 | 0 | 0 | |||
| FOXA1 | 0 | 0 | |||
| FOS | 骨上皮样血管瘤 | 厄贝沙坦, | 2 | 2 | |
| FOLR3 | 0 | 0 | |||
| FOLH1 | 0 | 0 | |||
| FNTB | 卵巢癌 | 洛那法尼, | 1 | 1 | |
| FNTA | 0 | 0 | |||
| FNDC4 | 0 | 0 | |||
| FN1 | 0 | 0 | |||
| FMR1 | 0 | 0 | |||
| FMO1 | 0 | 0 | |||
| FMN2 | 0 | 0 | |||
| FLT4 | 血管肉瘤 | 帕唑帕尼,培唑帕尼, | 1 | 1 | |
| FLT3 | 急性髓细胞白血病,急性早幼粒细胞白血病,成人B淋巴细胞白血病,结直肠癌,肾细胞癌 | Tyrphostin,All-trans Retinoic Acid,AS602868,Gilteritinib,JQ1,Lestaurtinib (CEP-701),米哚妥林,坦度替尼,尼洛替尼,哌柏西利,帕博西尼,帕博西林,帕纳替尼/普纳替尼/波纳替尼,奎扎替尼,Quizartinib (AC220),瑞戈非尼,司美替尼,索拉非尼,舒尼替尼,SU5614,舒尼替尼, | 蒽环类,阿糖胞苷,柔红霉素, | 15 | 82 |
| FLT1 | 0 | 0 | |||
| FLOT1 | 0 | 0 | |||
| FLNC | 0 | 0 | |||
| FLNA | 0 | 0 | |||
| FLI1 | 尤因肉瘤 | 2 | 2 | ||
| FLG | 0 | 0 | |||
| FLCN | 乳头状肾细胞癌 | 依维莫司,Sirolimus [USAN:BAN:INN], | 2 | 2 | |
| FKBP5 | 0 | 0 | |||
| FIP1L1 | 0 | 0 | |||
| FHIT | 0 | 0 | |||
| FH | 0 | 0 | |||
| FGR | 0 | 0 | |||
| FGFR4 | 肺泡横纹肌肉瘤,Her2受体阳性乳腺癌 | 多韦替尼,FGF/VEGF Receptor Tyrosine Kinase Inhibitor,PD173074,帕纳替尼/普纳替尼/波纳替尼, | 1 | 2 | |
| FGFR3 | 肾上腺癌,膀胱癌,癌症,肺腺癌,骨髓瘤,皮肤黑色素瘤,thanatophoric发育不良,最常见的形式是散发性,致死性侏儒症,尿路上皮癌 | AZ12908010,AZD4547,Infigratinib,Infigratinib,多韦替尼,厄达替尼,厄达替尼,帕唑帕尼,培唑帕尼,PD173074,SU5402,维莫非尼, | 20 | 29 | |
| FGFR2 | 乳腺癌,癌,胆管癌,子宫内膜癌,肝细胞癌,肺腺癌,卵巢透明细胞癌,乳头状肾细胞癌,直肠癌,胃癌,尿路上皮癌 | 46834118,AZD4547,Infigratinib,Infigratinib,Derazantinib,多韦替尼,厄达替尼,氟维司群,厄达替尼,帕唑帕尼,培唑帕尼,PD173074,帕纳替尼/普纳替尼/波纳替尼,Futibatinib, | 12 | 29 | |
| FGFR1 | 膀胱癌,骨尤因肉瘤,乳腺癌,癌症,慢性骨髓单核细胞白血病,慢性骨髓增生性疾病,结直肠癌,雌激素受体阳性乳腺癌,胃腺癌,头颈部鳞状细胞癌,血液癌,肺癌,非小细胞肺癌,肺鳞状细胞癌细胞癌,小儿低级别胶质瘤（PLGG）,毛细胞性星形细胞瘤,肉瘤 | AZD4547,Infigratinib,Infigratinib,多韦替尼,Dovitinib Dilactic Acid (TKI258 Dilactic Acid),FGF/VEGF Receptor Tyrosine Kinase Inhibitor,PD173074,米哚妥林,帕唑帕尼,培唑帕尼,帕纳替尼/普纳替尼/波纳替尼, | 4-羟基他莫昔芬, | 7 | 32 |
| FGF7 | 0 | 0 | |||
| FGF6 | 0 | 0 | |||
| FGF4 | 0 | 0 | |||
| FGF3 | 乳腺癌,肝细胞癌 | 多韦替尼,索拉非尼, | 1 | 2 | |
| FGF23 | 0 | 0 | |||
| FGF2 | 急性髓性白血病 | Quizartinib (AC220), | 1 | 1 | |
| FGF19 | 0 | 0 | |||
| FGF16 | 0 | 0 | |||
| FGF14 | 0 | 0 | |||
| FGF13 | 前列腺癌 | 1 | 1 | ||
| FGF12 | 0 | 0 | |||
| FGF10 | 0 | 0 | |||
| FGD4 | 0 | 0 | |||
| FGD1 | 0 | 0 | |||
| FGA | 0 | 0 | |||
| FES | 0 | 0 | |||
| FCRL4 | 0 | 0 | |||
| FCGR3B | 0 | 0 | |||
| FCGR3A | 乳腺癌 | 曲妥珠单抗, | 1 | 2 | |
| FCGR2C | 0 | 0 | |||
| FCGR2B | 乳腺癌 | 1 | 1 | ||
| FCGR2A | 乳腺癌 | 1 | 2 | ||
| FCGR1A | 0 | 0 | |||
| FBXW7 | 癌症,结直肠癌,肾细胞癌,T细胞急性淋巴细胞白血病 | 西妥昔单抗,依维莫司,MTOR Inhibitors,帕尼单抗,西罗莫司,瑞戈非尼, | 9 | 12 | |
| FBXO11 | 0 | 0 | |||
| FBXL7 | 0 | 0 | |||
| FBN2 | 0 | 0 | |||
| FAT4 | 0 | 0 | |||
| FAT3 | 0 | 0 | |||
| FAT2 | 0 | 0 | |||
| FAT1 | 0 | 0 | |||
| FASLG | 0 | 0 | |||
| FAS | 0 | 0 | |||
| FAP | 0 | 0 | |||
| FANCM | 0 | 0 | |||
| FANCL | 0 | 0 | |||
| FANCI | 0 | 0 | |||
| FANCG | 0 | 0 | |||
| FANCF | 0 | 0 | |||
| FANCE | 0 | 0 | |||
| FANCD2 | 0 | 0 | |||
| FANCC | 胰腺癌 | 马法兰，米尔法兰,丝裂霉素C, | 苯丁酸氮芥,顺铂,吉西他滨, | 1 | 1 |
| FANCB | 0 | 0 | |||
| FANCA | 前列腺癌 | 顺铂, | 1 | 1 | |
| FAN1 | 0 | 0 | |||
| FAM46C | 0 | 0 | |||
| FAM175A | 0 | 0 | |||
| FAM157B | 0 | 0 | |||
| FAM155A | 0 | 0 | |||
| FAM153B | 0 | 0 | |||
| FAM149A | 0 | 0 | |||
| FAM135B | 0 | 0 | |||
| FAM131B | 0 | 0 | |||
| FAF1 | 0 | 0 | |||
| F8 | 0 | 0 | |||
| F3 | 0 | 0 | |||
| F13A1 | 0 | 0 |
Copyright © 2020 基因医生
京ICP备13051264号-65 
京公网安备
11010802036025号